An atypical papillary lesion of the breast is a growth inside a milk duct that has abnormal-looking cells but has not crossed the line into cancer. It sits in an uncomfortable middle zone: not clearly harmless, not clearly dangerous. The “papillary” part refers to the finger-like projections of tissue that characterize these growths, and “atypical” means that a pathologist, looking under a microscope, sees cells that are dividing or arranging themselves in ways that are not quite normal. What makes this diagnosis particularly challenging is that a core needle biopsy can underestimate what is actually going on, so most women who receive this finding are told they need surgical excision to get a definitive answer.
Where Atypical Papillary Lesions Fit in the Spectrum
Papillary lesions of the breast are a broad family. At one end are benign papillomas, which are entirely harmless wart-like growths in the ducts. At the other end are invasive papillary carcinomas. In between sit several intermediate categories: papillomas with focal atypia, papillomas harboring ductal carcinoma in situ (DCIS), papillary DCIS itself, encapsulated papillary carcinomas, and solid papillary carcinomas.1Europe PMC. Papillary lesions of the breast An “atypical papillary lesion” typically refers to a papilloma in which a pathologist finds atypical ductal hyperplasia, meaning the cells lining the duct have started to look and arrange themselves somewhat like the cells in DCIS, but not enough to warrant a cancer diagnosis.
The concept of a continuum is central here. Intraductal proliferations of the breast run from ordinary hyperplasia through atypical hyperplasia to DCIS, with atypical hyperplasia occupying the midpoint between clearly benign and clearly malignant.2W.B. Saunders / Annals of Diagnostic Pathology. Intraductal proliferations of the breast: A review of histologic criteria for atypical intraductal hyperplasia and ductal carcinoma in situ, including apocrine and papillary lesions When that midpoint atypia occurs within a papilloma, you get an atypical papillary lesion. In the European classification system, even fragments of a benign papilloma on biopsy are classified as B3, meaning a lesion of uncertain malignant potential, and excision is generally recommended. Atypia only raises the stakes further.
How These Lesions Are Discovered
Most people with papillary lesions are not experiencing pain. In a study of 70 symptomatic cases, about three-quarters came to attention because of nipple discharge, while roughly a quarter presented with a lump found during a physical exam.3ecancermedicalscience. Breast papillary lesions: an analysis of 70 cases Nipple discharge in papillary lesions is often bloody or blood-tinged, which understandably alarms people, though bloody discharge alone does not mean cancer. A sizable number of atypical papillary lesions, however, are discovered incidentally on screening mammograms or ultrasounds in women who have no symptoms at all.
On imaging, papillary lesions are frustratingly variable. They can appear as well-defined masses, as intraductal filling defects, or as areas of asymmetric density on mammography. The presence of a mass on mammography was the most common feature across benign, atypical, and malignant papillary lesion groups in one large radiopathological review.4PubMed Central. Spectrum of imaging findings of papillary breast disease: A radiopathological review in a tertiary center On ultrasound, malignant papillary lesions tend to be larger and show more internal blood flow than benign ones, but no single imaging feature reliably distinguishes benign from atypical or malignant papillary lesions. The upshot, confirmed across MRI, ultrasound, and mammography studies, is that tissue sampling is almost always necessary.5PubMed. Papillary lesions of the breast: MRI, ultrasound, and mammographic appearances
Contrast-enhanced ultrasound is one newer technique being explored. Researchers have found that when a papillary lesion shows heterogeneous enhancement and an enlarged area of enhancement on contrast-enhanced ultrasound, those features together improved accuracy in predicting atypical or malignant disease, with a combined specificity around 83%.6European Journal of Radiology. Papillary breast lesions detected using conventional ultrasound and contrast-enhanced ultrasound: Imaging characteristics and associations with malignancy This is promising but not yet standard practice everywhere.
Why a Core Biopsy Often Isn’t Enough
This is perhaps the single most important thing to understand if you or someone you know has been told they have an atypical papillary lesion: the core needle biopsy that identified it may be underestimating the actual situation. A core biopsy takes small samples from the lesion. It is entirely possible for a needle to sample the atypical portion while missing a focus of DCIS or invasive cancer sitting right next to it.
The numbers bear this out consistently across studies. In one large series, papillary lesions with atypia on core biopsy were upgraded to malignancy at surgical excision about a third of the time, compared to under 8% for papillary lesions without atypia.7PubMed Central. Factors associated with disease upgrading in patients with papillary breast lesion in core-needle biopsy Another institution found that 27% of atypical intraductal papillomas were upgraded on excision, while only 3% of pure (non-atypical) papillomas were.8Human Pathology. Upgrade rate of intraductal papilloma diagnosed on core needle biopsy in a single institution A third study of 30 surgically excised atypical papillomas found malignancy in about 23%.9PubMed. Atypical papilloma diagnosed by sonographically guided 14-gauge core needle biopsy of breast mass
So when doctors recommend surgical excision after a core biopsy showing atypia in a papilloma, they are not being alarmist. Roughly one in four of these lesions turns out to harbor something worse than the biopsy suggested. That is a high enough rate that watchful waiting is generally not considered safe practice for atypical papillary lesions.
What Pathologists Look For Under the Microscope
Distinguishing a benign papilloma from an atypical one or a malignant one can be genuinely difficult, even for experienced pathologists. In normal papillomas, you typically see a fibrovascular core (a stalk of tissue with blood vessels) surrounded by two cell types: an inner epithelial layer and an outer myoepithelial layer. Pathologists use special stains, including cytokeratin 5/6 (CK5/6) and p63, to highlight the myoepithelial layer. In benign papillomas, this layer is intact and prominent.
One study of 127 excised papillary lesions found that broad, sclerotic fibrovascular cores combined with positive CK5/6 staining were most commonly seen in benign papillomas. Importantly, the combination of fibrovascular core thickness and CK5/6 staining could distinguish benign from malignant lesions, but it could not reliably separate benign from atypical cases.10Modern Pathology. Diagnostic evaluation of papillary lesions of the breast on core biopsy This is a telling finding: the gray zone between benign and atypical is real, and even immunohistochemistry cannot always resolve it on a core biopsy specimen. It is one of the reasons surgical excision becomes so important when atypia is suspected.
Digital pathology and artificial intelligence tools are being developed to help with exactly these borderline cases. Atypical and low-grade breast lesions account for a significant portion of diagnostic variability among pathologists, and AI may eventually help reduce disagreement. But for now, the final determination still rests with the pathologist’s judgment applied to surgically excised tissue.
Long-Term Cancer Risk After Diagnosis
Even when an atypical papillary lesion is fully removed and no cancer is found at excision, the diagnosis carries long-term implications. Having atypia inside a papilloma signals that the breast tissue has an elevated tendency to develop cancer down the road.
One study followed patients after excision and found that those with atypical papillomas had a five-year risk of developing invasive or in situ breast cancer of 13%, compared to about 5% for patients whose papillomas had no atypia.11PubMed. Risk of invasive breast cancer and ductal carcinoma in situ in women with atypical papillary lesions of the breast Looking further out, the ten-year risk of ipsilateral (same-breast) cancer or DCIS development was about 21% for the atypical group.12Cancer Research. Risk of Invasive Breast Cancer and Ductal Carcinoma In-Situ in Women with Atypical Papillary Lesions of the Breast The fact that most subsequent cancers tend to develop in the same breast, often near the original papilloma site, suggests this is not just a generalized risk marker but a signal about that particular area of breast tissue.13Cancer. Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma
The relative risk of invasive cancer for women whose papillomas contain atypical hyperplasia is more than four times higher than for women with papillomas without atypia. If additional atypical hyperplasia is found outside the papilloma in surrounding breast tissue, the risk may be even greater.13Cancer. Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma All of this means that women with this diagnosis are typically recommended for enhanced surveillance, often including annual mammography and sometimes breast MRI.
Treatment and Management Options
For atypical papillary lesions found on core biopsy, surgical excision is the standard recommendation. The goal is twofold: to rule out a more serious diagnosis that the biopsy may have missed, and to remove the abnormal tissue entirely. The surgery is usually a lumpectomy-type procedure, removing the area of concern with a margin of surrounding tissue.
In a study of 341 papillary breast lesions, papillomas without atypia that were treated by open excision or vacuum-assisted biopsy had similar outcomes, suggesting that for purely benign papillomas, a less invasive approach can be sufficient.14PubMed. Treatment and Outcome of 341 Papillary Breast Lesions Vacuum-assisted excision, a percutaneous technique that removes tissue through a larger-bore needle under imaging guidance, has also been studied for papillomas with atypia. One study concluded that vacuum-assisted excision was applicable for completely removing small papillomas, even those with atypical hyperplasia, with a low rate of underestimation and recurrence.15PubMed Central. Breast papillary lesions diagnosed and treated using ultrasound-guided vacuum-assisted excision However, there is ongoing debate about whether vacuum-assisted excision is adequate for atypical lesions versus open surgical excision. Many breast centers still prefer open excision for atypical papillomas to ensure the most reliable assessment.
Risk Reduction With Medication
Because atypical papillary lesions confer an elevated long-term breast cancer risk, your doctor may discuss preventive medication, sometimes called chemoprevention. Tamoxifen has been shown to be effective in preventing subsequent breast cancer in women with atypical hyperplasia, with reductions of more than 70% in one major prevention trial and about 60% in another.16PubMed Central. Impact of preventive therapy on the risk of breast cancer among women with benign breast disease These are striking numbers, though tamoxifen does come with side effects, and not every woman opts for it.
Available regimens depend partly on menopausal status. Both premenopausal and postmenopausal women can take tamoxifen, either at a standard dose for five years or, more recently, at a lower dose for three years. Postmenopausal women also have the option of raloxifene or aromatase inhibitors. Low-dose tamoxifen appears well tolerated, without the risk of serious adverse events seen at higher doses, and offers comparable risk reduction to other regimens.17PubMed. Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer Whether to pursue medication is a conversation with your doctor that weighs your individual risk factors, side effect tolerance, and preferences.
The Molecular Roots of Papillary Lesions
Research into what drives papillary lesions at the genetic level has revealed a surprisingly consistent picture. About two-thirds of papillary neoplasms harbor mutations in the PI3K/AKT signaling pathway, which governs cell growth and survival. In one pivotal study of 89 papillary lesions, 62% carried mutations, predominantly in AKT1 and PIK3CA.18PubMed. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast
What is interesting is how the mutation profile shifts as lesions become more abnormal. Simple papillomas without significant hyperplasia tend to carry more AKT1 mutations, while papillomas with florid hyperplasia or atypical hyperplasia tend to have more PIK3CA mutations.19Modern Pathology. Papillary neoplasms of the breast—reviewing the spectrum In another genomic study, PIK3CA was the most commonly mutated gene in intraductal papillomas, found in about 69% of cases. Lesions that were clonally related to co-existing carcinoma had distinct chromosomal copy number changes, including gains on chromosome 1q and losses on 16q and 11q, compared to pure papillomas without associated cancer.20npj Breast Cancer. The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma
This molecular work is not just academic. It hints at why some papillomas progress and others do not, and it may eventually guide decisions about which atypical papillary lesions truly require aggressive management. For now, though, genomic profiling is not part of routine clinical care for these lesions.
Malignant Papillary Variants Worth Knowing About
If you are reading about atypical papillary lesions, you will inevitably encounter terms like encapsulated papillary carcinoma (EPC) and solid papillary carcinoma (SPC). These are genuinely malignant papillary tumors, distinct from the atypical-but-not-yet-cancer diagnosis discussed above, and worth understanding as part of the landscape.
Encapsulated papillary carcinomas are surrounded by a fibrous capsule, and most behave in an indolent manner. Solid papillary carcinomas, by contrast, are more commonly associated with invasive carcinoma. In a study of 50 cases, SPCs were associated with invasion or considered invasive about 61% of the time, compared to roughly 22% of EPCs.21PubMed. Solid Papillary Carcinoma and Encapsulated Papillary Carcinoma of the Breast: Clinical-Pathologic Features and Basement Membrane Studies of 50 Cases Despite their different behaviors, both EPCs and SPCs share similar patterns of gene copy number alterations, though their gene expression profiles differ significantly, which likely explains their distinct appearances and clinical courses.22PubMed Central. Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast The existence of these malignant cousins is part of why any papillary lesion with atypia gets taken seriously: the line between atypical papilloma and papillary carcinoma can be thin, and it is not always obvious on a needle biopsy where a given lesion falls.
Atypical Papillary Lesions in Men
Breast papillary lesions are overwhelmingly a condition of women, but they can occur in men. A reported case involved a 51-year-old man who presented with painless, bloody nipple discharge from the left breast. Ultrasound showed an intraductal solid mass along with mild bilateral gynecomastia, and a core needle biopsy confirmed an atypical papillary lesion.23PubMed Central. A rare presentation of male breast atypical papillary lesion Male breast cancer itself is rare, and papillary lesions in men are rarer still, so evidence-based guidance specific to men is limited. The general approach mirrors what is done for women: imaging, tissue biopsy, and excision when atypia is found, because the histological spectrum from benign to malignant exists regardless of sex.
The Emotional Weight of the Diagnosis
Being told you have an “atypical” breast lesion can be deeply unsettling, and the terminology itself is part of the problem. Research into how patients experience borderline breast diagnoses has consistently found that labels like “pre-cancer,” “atypical,” and “abnormal” cause confusion and lasting anxiety. In one study, women with low-grade DCIS were confused and anxious because clinicians used terms like “pre-cancer” or “stage 0 cancer” but then described the condition as “only DCIS,” sending mixed signals about seriousness.24PubMed. Labels, Language, and Other Strategies to Improve Communication About Lower Grade Ductal Carcinoma in Situ: Theoretical Review A separate qualitative study found that all diagnostic labels prompted confusion and anxiety among patients, while physicians mistakenly perceived that patients understood the labels as implying low risk for cancer progression.25PubMed. Preferred labels and language to improve communication about lesions at low risk of progressing to cancer: qualitative interviews with patients and physicians
If you have received this diagnosis, it is reasonable to ask your doctor to explain in plain terms what the finding means for you specifically, what the recommended next steps are and why, and what your individual risk profile looks like. The word “atypical” does not mean cancer. It means abnormal cells that increase your risk and warrant further investigation. That distinction matters, and you should not leave an appointment without understanding it clearly.